GHK-Cu vs AHK-Cu
GHK-Cu is the copper(II) complex of glycyl-L-histidyl-L-lysine, an endogenous human plasma tripeptide with a research literature reaching back decades. AHK-Cu is the copper complex of alanyl-L-histidyl-L-lysine, a structural analogue in which glycine is replaced by alanine, used cosmetically under names adjacent to Tripeptide-3. The single-residue difference invites the assumption that the two are interchangeable, which is why they are so often set side by side in cosmetic and hair-loss material. No study has compared them directly in any model, and their evidence bases differ enormously in size. The research entry for AHK-Cu in this library states the same conclusion: no controlled comparison of AHK-Cu against GHK-Cu has been published.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No published study has tested GHK-Cu and AHK-Cu against each other in the same experiment, in any model, in vitro or in vivo. Searches of PubMed and Europe PMC returned no controlled comparison; the small number of records naming both are narrative reviews of short peptides in hair loss and cosmetic formulation papers rather than comparative experiments. The principal AHK-Cu dermatological source, a 2007 human hair follicle organ culture and dermal papilla cell study, cites the GHK-Cu literature as background but tested only AHK-Cu, with no GHK-Cu arm. Any comparison between the two is therefore indirect, assembled from separate studies that used different cell types, different concentration ranges, different endpoints and different decades of methodology, which limits what can be concluded about their relative activity.
Side by side.
| GHK-Cu | AHK-Cu | |
|---|---|---|
| Evidence maturity | Early clinical | Preclinical only |
| Studies cited here | 15 | 10 |
| Published 2023 or later | 10 | 6 |
| Newest paper | 2026 | 2026 |
| Sequence and origin | Glycyl-L-histidyl-L-lysine complexed with copper(II). GHK is an endogenous constituent of human plasma that binds copper with high affinity, so the peptide has a described physiological role independent of any product. | Alanyl-L-histidyl-L-lysine complexed with copper(II), a synthetic analogue in which the N-terminal glycine of GHK is substituted with alanine. It is not described as an endogenous human plasma peptide. |
| Size of the direct evidence base | Several decades of in vitro, animal and human work, including a 2026 PRISMA systematic review that screened the literature from database inception to March 2026 and identified 20 eligible studies, 18 preclinical and 2 randomised controlled trials. | Very small. A single 2007 ex vivo and cell-culture study is the principal dermatological source, supplemented by one topical delivery study of Tripeptide-3 and work on a vitamin C-conjugated AHK derivative in a non-cutaneous osteogenic model. |
| Best-characterised finding | Stimulation of collagen synthesis in cultured fibroblasts across a picomolar to nanomolar dose-response, first reported in 1988, together with gene-expression work describing broad modulation of extracellular-matrix, antioxidant and inflammatory programmes. | Elongation of human hair follicles in organ culture and proliferation of cultured dermal papilla cells, with an elevated Bcl-2/Bax ratio and reduced levels of cleaved caspase-3 and PARP. The reduction in the number of apoptotic dermal papilla cells was not statistically significant. |
| Human data | Present but thin and inconsistent. The two largest randomised trials of topical copper tripeptide, in venous stasis ulcers (1992, 86 evaluable patients) and on CO2 laser-resurfaced skin (2006, 13 completers), found no significant benefit on objective endpoints. The 2026 systematic review located only two randomised controlled trials of GHK-Cu as a standalone aesthetic intervention. | No published human clinical trial of AHK-Cu for hair growth or skin appearance. The one study with a human-skin component tested formulation delivery and facial oil reduction for Tripeptide-3 rather than the peptide's biological activity against a comparator. |
| Evidence maturity | Early clinical: controlled human trials exist, but their results are mixed, and most positive human reports come from uncontrolled studies of multi-ingredient formulations. | Preclinical only: the dermatological evidence is ex vivo and cell culture, and nothing comparable to the 2007 study has been published since. |
| Recency of primary research | Active, with in vitro, Caenorhabditis elegans and formulation studies published in 2025 and 2026 alongside the 2026 systematic review. | Dormant with respect to the peptide itself. No study published from 2023 onward addresses AHK-Cu directly; recent records naming it are reviews of the short-peptide class. |
| Basis of most marketing claims | Extrapolation from in vitro collagen and gene-expression data to topical cosmetic outcomes that the controlled trials did not confirm. | Extrapolation from the wider copper-tripeptide class, including the GHK-Cu literature, rather than from AHK-specific data. |
And what it does not.
Nothing in the published record establishes how these two peptides compare, because no experiment has ever run them side by side. What the separate literatures support is asymmetric rather than contradictory: GHK-Cu has decades of mechanistic in vitro data and a small, mixed set of controlled human trials, two of the largest of which found no significant advantage over comparator or placebo; AHK-Cu has essentially one dermatological experiment from 2007 in ex vivo follicles and cultured cells, and no human trial at all. The shared histidyl-lysine copper-binding motif makes a shared mechanism plausible, but plausibility is not data, and the 1991 mouse work on peptide copper complexes did not resolve which analogue does what. Neither peptide has an established dose-response for a topical cosmetic effect in humans, and skin permeation from cosmetic vehicles is not well characterised for either. A reader looking for a published basis to prefer one over the other will not find it in the literature as it stands.
Common questions.
- Is AHK-Cu simply a more stable version of GHK-Cu?
That framing is not supported by published comparative data, because no study has measured the stability or activity of the two complexes under the same conditions. The structural difference is the substitution of the N-terminal glycine with alanine. What effect that substitution has on copper affinity, skin permeation or biological potency relative to GHK-Cu has not been reported in a head-to-head experiment.
- What did the 2007 hair follicle study actually test?
It evaluated AHK-Cu alone on human hair follicles in organ culture and on cultured human dermal papilla cells. AHK-Cu stimulated follicle elongation and dermal papilla cell proliferation, raised the Bcl-2/Bax ratio and reduced cleaved caspase-3 and PARP levels. The reduction in the number of apoptotic dermal papilla cells did not reach statistical significance, and no GHK-Cu comparator arm was included.
- Do the copper tripeptide wound-healing trials tell us anything about cosmetic use?
Only indirectly, and the direction is cautionary. The 1992 prospective randomised evaluator-blinded trial in venous stasis ulcers and the 2006 randomised trial on CO2 laser-resurfaced skin both used topical copper tripeptide complex, and neither found a significant benefit on its objective endpoints. Those are wound-repair and post-procedure settings rather than routine cosmetic application, so they neither confirm nor exclude an effect on the appearance of intact skin.
- Why do so many product descriptions treat the two peptides as equivalent?
Because the AHK-specific literature is too small to source claims from, so material about AHK-Cu is generally written from the wider copper-tripeptide class, of which GHK-Cu is the most studied member. The research entries in this library flag that directly: claims about AHK-Cu efficacy in cosmetic use are extrapolations from class data rather than findings about AHK-Cu itself.
- Has either peptide been shown to reach the dermis after topical application?
Skin permeation of GHK-Cu from cosmetic vehicles is not well characterised in the published literature, and no dose-response for a topical anti-wrinkle effect has been established in humans. For AHK-Cu the delivery question has been approached through formulation work on microemulsions and nanoemulsions for Tripeptide-3, which addressed vehicle design and facial oil reduction rather than demonstrating dermal delivery of the intact copper complex.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.